US Patent

US7989589 — Compstatin analogs with improved activity

Composition of Matter · Assigned to University of Pennsylvania Penn · Expires 2027-12-04 · 2y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent discloses compounds, including peptides and peptidomimetics, that can bind to the C3 protein and inhibit complement activation.

USPTO Abstract

Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number: US7989589
Jurisdiction: US
Classification: Composition of Matter
Expires: 2027-12-04
Drug substance claim: Yes
Drug product claim: No
Assignee: University of Pennsylvania Penn
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.